Stivarga Regorafenib 40 Mg Tablet

Get a Price/Quote

MOQ : 10 Pieces

Stivarga Regorafenib 40 Mg Tablet Specification

Brand Name
Stivarga

Salt Composition
Regorafenib 40 mg

Dosage Form
Oral tablet

Life Span
Check expiry date on packaging

Pacakaging (Quantity Per Box)
28 tablets

Packaging Type
Box/Blister pack

Origin of Medicine
Germany

Indication
Metastatic colorectal cancer, gastrointestinal stromal tumors, hepatocellular carcinoma

Drug Type
Prescription drug (Rx)

Ingredients
Regorafenib

Physical Form
Tablet

Function
Antineoplastic (cancer treatment)

Recommended For
Patients with metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (as prescribed by physician)

Dosage
Typically 160 mg orally once daily for 21 days, followed by 7 days off treatment (as directed by healthcare professional)

Dosage Guidelines
Take at the same time each day, as prescribed by healthcare provider

Suitable For
Adults only

Quantity
28 tablets per box

Storage Instructions
Store below 30C, protect from moisture and light, keep out of reach of children

Color
Light pink tablet

Prescription/Non Prescription
Prescription required

Strength
40 mg

Administration Route
Oral

Side Effects
May include hypertension, fatigue, diarrhea, hand-foot skin reaction, decreased appetite, voice changes

Therapeutic Class
Oncology

Contraindications
Not recommended for use in pregnancy or individuals with known hypersensitivity to Regorafenib

Marketed Countries
Available in Canada, EU, UK, USA, Australia

Approval
US FDA Approved

About Stivarga Regorafenib 40 Mg Tablet

Take advantage of the acclaimed Stivarga Regorafenib 40 mg Tablet, a brilliant antineoplastic therapy for dominant cancer management. With a sizzling track record in oncology, this exceptional prescription drug is US FDA approved and trusted worldwide in metastatic colorectal cancer, GIST, and hepatocellular carcinoma. Each light pink, oral tablet delivers 40 mg Regorafenib, providing substantial support under medical guidance. Not recommended for pregnant individuals or those with hypersensitivity. Available in Australia, Canada, UK, EU, and USA, it is supplied in secure, moisture-protected packaging. Experience breakthrough cancer care-responsibly.

Stivarga Regorafenib 40 Mg Tablet: Usage & Applications

Stivarga Regorafenib 40 mg Tablet is primarily used for treating metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. Utilized in top oncology centers and hospitals, this medicine is recommended for adults under strict medical supervision. Its proven efficacy in challenging cancer types makes it a preferred choice among oncologists internationally. Stivarga is taken orally, as prescribed, making it adaptable for outpatient or inpatient cancer treatment settings.

Stivarga Regorafenib 40 Mg Tablet: Supply Ability, Certifications & Delivery Time

We offer consistently reliable supply ability for Stivarga Regorafenib 40 mg Tablet, with all shipped goods certified by the US FDA and related authorities. Each shipment is carefully packed and labeled for safety and compliance. We ensure prompt delivery, so patients and healthcare providers experience minimal delays in obtaining treatment. Our shipment process is streamlined and adheres to high standards-allowing you to receive genuine, quality-certified oncology medication.

FAQ's of Stivarga Regorafenib 40 Mg Tablet:

Q: How should Stivarga Regorafenib 40 Mg Tablet be administered for optimal benefit?

A: Stivarga should be taken exactly as prescribed by your healthcare provider-usually 160 mg once daily for 21 days, followed by 7 days off. It is important to take it at the same time each day and only by mouth, with or without food, as directed.

Q: What are the primary therapeutic uses of Stivarga Regorafenib 40 Mg Tablet?

A: This medicine is primarily used for adult patients with metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma, when prescribed by a physician.

Q: When should Stivarga NOT be used?

A: Stivarga should not be used during pregnancy or by individuals known to have a hypersensitivity to Regorafenib. Careful screening and physician assessment are advised before starting treatment.

Q: Where is Stivarga Regorafenib 40 Mg Tablet available?

A: This medication is marketed and available in several countries, including Canada, the EU, UK, USA, and Australia, supplied from Germany and distributed worldwide via certified suppliers, manufacturers, and traders.

Q: What are the possible side effects associated with Stivarga?

A: Common side effects include hypertension, fatigue, diarrhea, hand-foot skin reaction, decreased appetite, and changes in voice. It is crucial to monitor your health during therapy and report any concerns to your healthcare provider immediately.

Tell us about your requirement